Bli medlem
Bli medlem

Du är här

2016-11-15

MorphoSys AG: MorphoSys Announces That Its Licensee Janssen Has Presented Positive Clinical Data of Guselkumab in Psoriatic Arthritis

MorphoSys AG / MorphoSys Announces That Its Licensee Janssen Has Presented
Positive ClinicalData of Guselkumab in Psoriatic Arthritis . Processed and
transmitted by Nasdaq Corporate Solutions.The issuer is solely responsible
for the content of this announcement.
Phase 2a Clinical Study Results in Patients with Active Psoriatic Arthritis
Presented at the American College of Rheumatology (ACR/ARHP) Meeting

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced
today that its licensee Janssen Research&Development, LLC (Janssen) has
presented results from a randomized, double-blind, placebo-controlled
clinical phase 2a study examining guselkumab in the treatment of active
psoriatic arthritis. Guselkumab is a fully human anti-IL-23 monoclonal
antibody discovered by Janssen utilizing the HuCAL antibody library
technology licensed from MorphoSys.

According to a press release issued by Janssen today, a substantially higher
percentage of patients receiving guselkumab achieved at least a 20 percent
improvement in signs and symptoms of the disease (ACR 20) at week 24, the
study's primary endpoint, compared with patients receiving placebo. In
addition, according to Janssen's press release, data from the trial also
showed statistically significant improvements in all secondary endpoints
including physical function, psoriatic skin lesions and other health related
outcomes in patients treated with guselkumab compared with patients receiving
placebo.

Janssen will present the detailed data, thecorresponding abstract of which can
be seen here, in a late breaking session today, November 15, 2016, from
4:30pm-6pm (EST) (10:30pm-12:00am CET) at the Annual Meeting of the American
College of Rheumatology (ACR/ARHP) in Washington, DC/USA. The title of the
abstract submitted by Janssen is: "Efficacy and Safety Results of Guselkumab,
an Anti-IL23 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis
over 24 Weeks: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled
Study."

"After Janssen already reported positive data for guselkumab from a phase 3
study in moderate to severe plaque psoriasis in October 2016, we are pleased
that positive clinical phase 2a results with guselkumab have now been
reported also in the treatment of active psoriatic arthritis", said Dr.
Marlies Sproll, Chief Scientific Officer of MorphoSys AG.
Further detailed information about the clinical study results can be found in
a press release issued by Janssen today.

About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a
therapeuticpipelineof more than 100 human antibody drug candidates for the
treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name
just a few. With its ongoing commitment to new antibody technology and drug
development, MorphoSys is focused on making the healthcare products of
tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the
symbol MOR. For regular updates about MorphoSys,
visithttp://www.morphosys.com.

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®,
100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are
registered trademarks of the MorphoSys Group.

This communication contains certain forward-looking statements concerning the
MorphoSys group of companies, The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and
involve risks and uncertainties. Should actual conditions differ from the
Company's assumptions, actual results and actions may differ from those
anticipated, MorphoSys does not intend to update any of these forward-looking
statements as far as the wording of the relevant press release is concerned.

For more information, please contact:
MorphoSys AG
Anke Linnartz
Head of Corporate Communications&IR

Jochen Orlowski
Associate Director Corporate Communications&IR

Alexandra Goller
Senior Manager Corporate Communications&IR

Tel: +49 (0) 89 / 899 27-404
investors@morphosys.com

Media Release (PDF)
http://hugin.info/130295/R/2057051/770635.pdf

---------------------------------------
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MorphoSys AG via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.